Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions

Journal of Endovascular Therapy

Volumn 21, Issue 3, 2014, Pages 359-368

  Zeller, Thomas ^a   Rastan, Aljoscha ^a   Macharzina, Roland ^a   Tepe, Gunnar ^b   Kaspar, Matthias ^a   Chavarria, Jorge ^a   Beschorner, Ulrich ^a   Schwarzwal̈der, Uwe ^a   Schwarz, Thomas ^a   Noory, Elias ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b Klinikum Rosenheim   (Germany)

Author keywords

Drug coated balloon; Drug eluting balloon; Drug eluting stent; Femoropopliteal segment; Occlusion; Paclitaxel; Peripheral artery disease; Popliteal artery; Provisional stenting; Restenosis; Stenosis; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; BIOMATERIAL; CARDIOVASCULAR AGENT;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BALLOON; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CAOTED BALLOON; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FEMOROPOPLITEAL LESION; FOLLOW UP; GOLD STANDARD; HUMAN; IN-STENT RESTENOSIS; LIMB ISCHEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NITINOL STENT; OCCLUSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; BLOOD FLOW VELOCITY; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMORAL ARTERY; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS; RECURRENT DISEASE; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME; TREATMENT OUTCOME; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; BLOOD FLOW VELOCITY; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS DESIGN; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 84903171609     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/13-4630MR.1     Document Type: Article

References (32)

1. Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003;37:149-155. (Pubitemid 36236959)
2. Pereira CE, Albers M, Romiti M, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006;44:510-517.
3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67.
4. Abbott WM, Green RM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-knee Femoropopliteal Study Group. J Vasc Surg. 1997;25:19-28. (Pubitemid 27081605)
5. Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg. 2000;31:417-425. (Pubitemid 30158002)
6. Devine C, McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg. 2004;40:924-931. (Pubitemid 39535222)
7. Jensen LP, Lepäntalo M, Fossdal JE, et al. Dacron of PTFE for above-knee femoropopliteal bypass. A multicenter randomized study. Eur J Vasc Endovasc Surg. 2007;34:44-49. (Pubitemid 46863199)
8. Nydahl S, Hartshorne T, Bell PR, et al. Subintimal angioplasty of infrapopliteal occlusions in critically ischaemic limbs. Eur J Vasc Endovasc Surg. 1997;14:212-216. (Pubitemid 27448108)
9. Laxdal E, Jenssen GL, Pedersen G, et al. Subintimal angioplasty as a treatment of femoro-popliteal artery occlusions. Eur J Vasc Endovasc Surg. 2003;25:578-582. (Pubitemid 36701799)
10. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888. (Pubitemid 43872689)
11. Laird JR, Katzen BT, Scheinert D, et al.; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
12. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261-269.
13. Bosiers M, Deloose K, Callaert J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042-1050.
14. Rastan A, Krankenberg H, Baumgartner I, et al. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multi-centre, randomized trial. Circulation. 2013;127:2535-2541.
15. Lammer J, Zeller T, Hausegger K, et al. Heparin-bonded covered stents versus bare metal stents for symptomatic peripheral arterial disease: the VIASTAR trial. J Am Coll Cardiol. 2013;62:1320-1327.
16. Dake MD, Scheinert D, Tepe G, et al.; Zilver PTX Single-Arm Study Investigators. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613-623.
17. Dake MD, Ansel GM, Jaff MR, et al. on behalf of the Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: 12-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504.
18. Dake M, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: two-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417-2427.
19. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699. (Pubitemid 351240748)
20. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
21. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-840.
22. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10-19.
23. Micari A, Cioppa A, Vadala G, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331-338.
24. Micari A, Cioppa A, Vadala G, et al. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv. 2013;6:282-289.
25. Bosiers M, Peeters P, Tessarek J, et al. The Zilver PTX Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54:115-22.
26. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333. (Pubitemid 29383480)
27. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24:295-313.
28. Schmieder GC. Endovascular superficial femoral artery treatment: can it be as good as bypass? Sem Vasc Surg. 2008;21:186-194.
29. Davaine JM, Azéma L, Guyomarch B, et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (The STELLA "STEnting Long de L'Artère fémorale superficielle" Cohort). Eur J Vasc Endovasc Surg. 2012;44:432-441.
30. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation vs. percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007;116:285-292. (Pubitemid 47196564)
31. Duda SH, Bosiers M, Lammer J, et al., for the SIROCCO study group. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338. (Pubitemid 40354849)
32. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results fromthe SIROCCO trial. J Endovasc Ther. 2006;13:701-710. (Pubitemid 44907633)